Acomplia Back-Up Compound Could Have Clearer Obesity Effect, Sanofi Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s “approvable” letter for Acomplia requests an additional clinical trial in treatment of smoking cessation, but not for obesity claim, firm says.
You may also be interested in...
Acomplia Is "Not Approvable" For Smoking Cessation, "Approvable" For Weight Loss
FDA issued a split decision for Sanofi-Aventis' rimonabant NDAs.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: